Literature DB >> 27065578

Clinicopathological Analysis of B Cell Lymphomas, Unclassifiable; with Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma in a Tertiary Care Hospital in Southern India.

Subramanian Kalaivani Selvi1, Rakhee Kar1, Debdatta Basu1, Sajini Elizabeth Jacob1, Biswajit Dubashi2.   

Abstract

B-cell lymphomas, unclassifiable; with features intermediate between large B-cell lymphoma and Burkitt lymphoma (BCLu-DLBCL/BL) is a new entity included in the recent World Health Organization (WHO) classification of Tumours of the Hematopoietic and Lymphoid Tissues (2008) to overcome the problems of difficulty in classifying certain lymphomas having overlapping morphological, immunophenotypical and genetic features. To study the clinicopathological profile of BCLu-DLBCL/BL. Cross-sectional study over 3 year period in the Haematology section of Department of Pathology in a large teaching hospital in Southern India from January 2011 to December 2013. All the cases reported as BCLu-DLBCL/BL were collected and the clinical, morphological and immunohistochemical parameters were analyzed. Descriptive statistics. There were seven cases, four males and three females, of age ranging from 20 to 70 years. Five cases had extranodal involvement. Four cases had Burkitt morphology with strong Bcl2 positivity and absent CD10 expression. One case had the morphology and immunophenotype that of typical BL, along with strong positivity to Bcl2 suggesting a double hit hypothesis. Two cases had morphology and immunophenotype of BL with low Ki 67. Three patients on follow up had adverse outcome. BCLu-DLBCL/BL, a provisional category in WHO 2008 is useful in classifying the cases not meeting the criteria for classical BL or DLBCL. Each of these cases was interesting with different sites of involvement, different morphological features and immunophenotype with most of the patients on follow up ending with a grave prognosis.

Entities:  

Keywords:  BCLu-DLBCL/BL; Burkitt lymphoma; Diffuse large Bcell lymphoma; Intermediate features; WHO 2008

Year:  2015        PMID: 27065578      PMCID: PMC4789012          DOI: 10.1007/s12288-015-0558-6

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN: 0971-4502            Impact factor:   0.900


  20 in total

1.  A case of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma in a Korean child.

Authors:  Jeong Yeal Ahn; Yiel Hea Seo; Pil Whan Park; Kyung Hee Kim; Mi Jung Park; Ji Hoon Jeong; Soon Ho Park; Young Hee Song
Journal:  Ann Lab Med       Date:  2012-02-23       Impact factor: 3.464

Review 2.  B-cell lymphomas with features intermediate between distinct pathologic entities. From pathogenesis to pathology.

Authors:  Antonino Carbone; Annunziata Gloghini; Antonella Aiello; Adele Testi; Antonello Cabras
Journal:  Hum Pathol       Date:  2010-05       Impact factor: 3.466

Review 3.  Double-hit B-cell lymphomas.

Authors:  Sietse M Aukema; Reiner Siebert; Ed Schuuring; Gustaaf W van Imhoff; Hanneke C Kluin-Nelemans; Evert-Jan Boerma; Philip M Kluin
Journal:  Blood       Date:  2010-11-30       Impact factor: 22.113

4.  Clinicopathological features of aggressive B-cell lymphomas including B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell and Burkitt lymphomas: a study of 44 patients from Argentina.

Authors:  María Virginia Bürgesser; Gabriela Gualco; Ana Diller; Yasodha Natkunam; Carlos E Bacchi
Journal:  Ann Diagn Pathol       Date:  2012-12-14       Impact factor: 2.090

5.  Commentary on the WHO classification of tumors of lymphoid tissues (2008): "Gray zone" lymphomas overlapping with Burkitt lymphoma or classical Hodgkin lymphoma.

Authors:  Robert P Hasserjian; German Ott; Kojo S J Elenitoba-Johnson; Olga Balague-Ponz; Daphne de Jong; Laurence de Leval
Journal:  J Hematop       Date:  2009-06-27       Impact factor: 0.196

Review 6.  Translocations involving 8q24 in Burkitt lymphoma and other malignant lymphomas: a historical review of cytogenetics in the light of todays knowledge.

Authors:  E G Boerma; R Siebert; P M Kluin; M Baudis
Journal:  Leukemia       Date:  2008-10-16       Impact factor: 11.528

7.  B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and burkitt lymphoma: study of 39 cases.

Authors:  Anamarija M Perry; David Crockett; Bhavana J Dave; Pamela Althof; Lisa Winkler; Lynette M Smith; Patricia Aoun; Wing C Chan; Kai Fu; Timothy C Greiner; Phillip Bierman; Robert Gregory Bociek; Julie M Vose; James O Armitage; Dennis D Weisenburger
Journal:  Br J Haematol       Date:  2013-04-18       Impact factor: 6.998

Review 8.  Workshop report on Hodgkin's disease and related diseases ('grey zone' lymphoma).

Authors:  T Rüdiger; E S Jaffe; G Delsol; C deWolf-Peeters; R D Gascoyne; A Georgii; N L Harris; M E Kadin; K A MacLennan; S Poppema; H Stein; L E Weiss; H K Müller-Hermelink
Journal:  Ann Oncol       Date:  1998       Impact factor: 32.976

9.  Pediatric B-cell lymphoma, unclassifiable, with intermediate features between those of diffuse large B-cell lymphoma and Burkitt lymphoma: a report of two cases.

Authors:  Shanxiang Zhang; David Wilson; Magdalena Czader
Journal:  Ann Lab Med       Date:  2015-02-12       Impact factor: 3.464

10.  Specific cytogenetic abnormalities are associated with a significantly inferior outcome in children and adolescents with mature B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 international study.

Authors:  H A Poirel; M S Cairo; N A Heerema; J Swansbury; A Aupérin; E Launay; W G Sanger; P Talley; S L Perkins; M Raphaël; K McCarthy; R Sposto; M Gerrard; A Bernheim; C Patte
Journal:  Leukemia       Date:  2008-11-20       Impact factor: 11.528

View more
  1 in total

1.  Treatment of grey zone lymphoma using the R-CODOX-M/R-IVAC protocol: Two case reports.

Authors:  Xiao-Yan Yang; Ling Jiang; Rong-Fei Jia; An-Ji Hou
Journal:  Medicine (Baltimore)       Date:  2017-09       Impact factor: 1.889

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.